THIS MONTH’S ISSUE

Read, save, and print articles from the current issue

ARTICLES

Chronological index
2013–2016

PRODUCT GUIDES

Compare all instruments
and software systems

DEPARTMENTS

Chronological index
2013–2016

MARKETPLACE

New pathology lab products and industry news

Home » Top news

BD Veritor meets new FDA flu requirements

March 17, 2017Becton Dickinson announced that its BD Veritor System Flu A+B, a digital immunoassay for the rapid detection of influenza, meets the new FDA performance requirements in which antigen-based rapid influenza virus antigen detection systems (RIDTs) intended to detect influenza virus directly from clinical specimens have been reclassified from class I devices to class II devices subject to special controls.

“The change to the new performance standards may help improve the overall quality of testing for influenza,” Charles Cooper, MD, vice president of medical affairs at BD, said in a statement. “This agency’s decision has the potential to improve patient outcomes— ensuring that the tools health care providers use for diagnosing influenza meet new, higher standards for accuracy. As we know, an accurate diagnosis helps to determine appropriate use of antiviral medications, while at the same time reducing inappropriate over-prescription of antibiotics, which can only help in the fight against antimicrobial resistance.”

The now-class II BD Veritor System Flu A+B test first became available in 2011 and is the same test used on the new BD Veritor Plus System, a next-generation wireless rapid diagnostic system for detection of influenza A and B, respiratory syncytial virus, and group A strep.

More top news

Print Friendly, PDF & Email
Tags:

X